(Q26766063)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Daniela Maria Cardinale

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

4

Carmen Criscitiello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Susan Dent

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Olexiy Aseyev

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Daniel Lenihan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Carlo Maria Cipolla

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

July 2016

0 references

published in

CA

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

309-325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

Trends in the leading causes of death in the United States, 1970-2002.

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Doxorubicin-induced cardiomyopathy treated with carvedilol.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Protective effects of spironolactone against anthracycline-induced cardiomyopathy.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Ifosfamide cardiotoxicity in humans

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Capecitabine-induced cardiotoxicity mimicking myocardial infarction

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiotoxicity due to Chemotherapy: the Role of Biomarkers

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiac complications of chemotherapy: role of biomarkers.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Clinical guide SEOM on venous thromboembolism in cancer patients

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Diastolic dysfunction after mediastinal irradiation

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Early detection and prediction of cardiotoxicity in chemotherapy-treated patients

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Comparison of Three-year outcomes after primary percutaneous coronary intervention in patients with left ventricular ejection fraction <40% versus ≥ 40% (from the HORIZONS-AMI trial)

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cancer therapy-induced left ventricular dysfunction: interventions and prognosis

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiotoxicity of cytotoxic drugs

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiovascular disease after cancer therapy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Beta-blockade intolerance in anthracycline-induced cardiomyopathy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Radiation dose-volume effects in the heart

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submi

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Insights into onco-cardiology: atrial fibrillation in cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Asymptomatic cardiac disease following mediastinal irradiation

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuita

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiotoxicity of anticancer treatments

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Risk of ischemic heart disease in women after radiotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

cTnT can be a useful marker for early detection of anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

https://api.crossref.org/works/10.3322%2FCAAC.21341

1 reference

7 January 2021

Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Recommendations for the evaluation of left ventricular diastolic function by echocardiography

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cancer drugs and the heart: importance and management

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

European Society of Cardiology Heart Failure Association Standards for delivering heart failure care

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Introducing a new entity: chemotherapy-induced arrhythmia.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Improved estimates of cancer-specific survival rates from population-based data

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Incidence of new-onset hypertension in cancer patients: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cancer and Cardiovascular Disease: The Complex Labyrinth

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Anthracycline-induced cardiotoxicity: cardiac monitoring by continuous wave-Doppler ultrasound cardiac output monitoring and correlation to echocardiography.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Rationale and design of the prevention of cardiac dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Angiographic findings 1 month after myocardial infarction: a prospective study of 259 survivors

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Pulmonary arterial hypertension in patients treated by dasatinib

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Thrombosis in multiple myeloma (MM).

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Development and validation of a predictive model for chemotherapy-associated thrombosis

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent tr

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epider

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Declining death rates reflect progress against cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Role of biomarkers in cardioncology

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cancer treatment and survivorship statistics, 2012

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Radiation-induced heart disease: pathologic abnormalities and putative mechanisms

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21341

7 January 2021

Identifiers

DOI

10.3322/CAAC.21341

2 references

Consolidated OpenCitations Corpus – April 2017

4307928

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

4307928

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

4307928

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26919165%20AND%20SRC:MED&resulttype=core&format=json